ASCO 2026 Readout — Competitive Implications for Zenvara
Prepared by Jordan Patel, CI Analyst. Distribution: VP Commercial, CCO, Medical Affairs Director, Launch Lead, HEOR Director, regional sales directors. Delivered Thursday May 14 EOD per Dana's request.
Headline
The most material development from the ASCO 2026 program affecting Zenvara is the BMS CheckMate-X Phase 3 readout in 2L NSCLC, which missed its primary progression-free survival endpoint. Reported HR 0.91 (95% CI 0.78-1.06), p=0.18. This result reduces the near-term 2L competitive threat from BMS materially; the HR confidence interval overlaps our last cut from ZENITH-2 (the 2L study, ongoing) of HR 0.71, and the CheckMate result is not a clean win for BMS over our likely positioning.
Sequence of events (WK19)
Tuesday May 12 10:00 ET — Jordan flagged on Slack that the CheckMate-X abstract title was visible in the ASCO 2026 supplement table of contents, with Kaplan-Meier reported at 18.2 months for the BMS arm. Our last public cut on the comparator was 17.6 months. The KM milestone was the first data point.
Tuesday May 12 14:00 ET — Karen Wu (MSL Lead) reviewed the abstract metadata and noted that the HR confidence interval overlaps the ZENITH-2 confidence interval based on the publicly available abstract title and the embargoed abstract preview. Her read: 'not a clean win for them.'
Tuesday May 12 16:00 ET — Dana Park (CCO) requested a one-page CI brief by EOD Thursday for executive distribution.
Wednesday May 13 09:00 ET — Internal congress alert noted that 4 abstracts in the Zenvara class lift embargo within 24 hours. Key abstracts: CheckMate-X 2L NSCLC (BMS), KEYNOTE-189 5-year update (Merck), DESTINY-Lung-XX (Daiichi/AZ), IMpower-YY (Roche).
Thursday May 14 11:00 ET — Embargo lifted on the CheckMate-X full abstract. Confirmed primary PFS endpoint missed; HR 0.91 (95% CI 0.78-1.06), p=0.18. Secondary OS endpoint also non-significant (HR 0.95).
Thursday May 14 14:00 ET — Jordan drafted this brief. Reviewed by Karen Wu and Dana Park.
Thursday May 14 18:30 ET — Final brief circulated.
CheckMate-X result detail
Trial: Phase 3 randomized, double-blind, BMS competitor (compound: nivolumab + relatlimab combination) vs nivolumab monotherapy in 2L metastatic NSCLC after progression on 1L immunotherapy.
Patient population: 600 randomized, balanced across PD-L1 expression strata.
Primary endpoint: PFS. Result: HR 0.91 (95% CI 0.78-1.06), p=0.18. Median PFS: 4.8 vs 4.2 months. Did not meet pre-specified statistical significance threshold (one-sided p < 0.025).
Secondary endpoints: OS HR 0.95 (95% CI 0.81-1.12), median OS 18.2 vs 17.6 months — not statistically significant. ORR 18% vs 14%. Grade 3+ AE rate 38% vs 32% (higher in combination arm).
Conclusion: trial did not demonstrate benefit of relatlimab addition to nivolumab in 2L NSCLC. BMS is unlikely to pursue label expansion in 2L based on this readout.
Implications for Zenvara — near-term (next 6 months)
Reduced defensive messaging requirement in 2L space. Our previously prepared talk track on BMS competitive risk can be relaxed; reps can refocus their share-of-voice on the 1L positive ZENITH-1 data without the BMS counter-positioning.
Patient-level: HCPs treating 2L NSCLC patients now face a more open competitive landscape with no clear standard for 2L post-IO. This creates a window for ZENITH-2 (our own 2L program, currently enrolling) to position upon readout (target Q3 2026).
Pricing: BMS pricing power in 2L NSCLC is reduced. Their commercial pressure to maintain net pricing in the existing IO franchise is now greater. Potential downstream: BMS may aggressively defend pembrolizumab market share in 1L through contracting, which could indirectly affect our 1L positioning.
Implications for Zenvara — mid-term (6-18 months)
BMS likely to pivot CheckMate program development to 1L combinations or earlier-line settings. The CheckMate-X failure removes one path; BMS will look for other readouts to anchor the 2L franchise.
Competitor monitoring tracker should be updated to reflect this — CheckMate-X moves from "high probability of approval in 2L" to "unlikely to seek 2L label".
MSL outreach unchanged. Karen continues Dr. Mehta (Sloan) engagement with the Optum RWE durability data Sara pulled in early May.
Other ASCO 2026 readouts affecting Zenvara (preliminary; embargo not yet lifted)
KEYNOTE-189 5-year update (Merck): 5-year OS data on first-line pembrolizumab + chemotherapy in NSCLC. Long-term durability data is expected to be positive. Implication: reinforces pembrolizumab as 1L SoC; modest competitive pressure on Zenvara 1L positioning.
DESTINY-Lung-XX (Daiichi Sankyo/AstraZeneca): trastuzumab deruxtecan in HER2-mutant NSCLC. Not in direct competition with Zenvara (different biomarker population).
IMpower-YY (Roche): atezolizumab data in 1L NSCLC PD-L1 high. Direct competitor positioning, but trial design differs from ZENITH-1. Karen will brief separately on Tuesday post-embargo.
Recommended actions
1. Update competitor monitoring tracker (1N5) to reflect CheckMate-X result.
2. Refresh defensive 2L messaging — replace BMS-pressure talk track with the new ZENITH-2 forward-looking story for 1L practice managers and KOLs.
3. Brief regional sales directors at Friday tracker call (Marco to schedule by EOD Thursday).
4. MSL panel session at the May 28 quarterly MSL convening to coordinate Karen + EU MSLs on consistent positioning.
5. CI team to monitor BMS public commentary at ASCO press briefings and during investor calls (BMS Q1 2026 earnings May 22). Looking for any signals on Q3-Q4 2026 program prioritization.
Cross-references
Competitor Monitoring Tracker (1N5…), KOL Advisory Board Apr 2026 Synthesis (1M2…), 2026 Congress Calendar (1O8…). ASCO source: /api/congress/abstracts?congress=ASCO2026. Slack thread: #competitive-intel (Jordan 10:00 ET Tuesday).